Photo taken from Matt Campbell/X
Apr 13, 2024, 09:52
Matt Campbell: The results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology
Matt Campbell, Genitorurinary medical oncologist at UT MD Anderson Cancer center, shared a post on X:
“HOT OFF THE PRESS: Happy to share the results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology from MD Anderson Cancer center.”
Source: Matt Campbell/X